source
- Lilly and FDA clash over retatrutide classification as company nears submissionEli Lilly is preparing to file its obesity drug candidate retatrutide for approval while a legal dispute with the FDA over the drug's classification intensifies. The agency has concluded that reta…
- FDA approves Takeda’s orexin receptor agonist for narcolepsy, opening new drug classThe FDA has granted approval to Takeda's novel narcolepsy medication, the first orexin receptor agonist to receive clearance. The twice‑daily pill, marketed as Orzeyful, is indicated for narcoleps…